Novel mutation in PIK3CD affecting the Ras-binding domain
Abstract
Introduction: The phosphoinositide 3-kinase (PI3K) pathway plays critical roles in diverse cellular processes, including differentiation, proliferation, motility, survival, and growth. PI3Kδ, comprised of the catalytic subunit p110δ and regulatory subunit p85α, is essential for normal lymphocyte and myeloid development and function. Gain-of-function mutations in PIK3CD (encoding p110δ) cause a combined immunodeficiency known as activated PI3Kδ syndrome (APDS), in which patients frequently present with recurrent respiratory infections, severe recurrent (or persistent) infections with herpes family viruses, and lymphadenopathy.
Aim: To describe the clinical presentation, immune evaluation, and genetic work-up of 2 patients (daughter and mother) with recurrent sinopulmonary, soft tissue, and skin infections.
Results: Both daughter and mother presented with recurrent sinopulmonary and soft tissue infections. Immune evaluation of the daughter revealed intermittent hypogammaglobulinemia and abnormal specific vaccine responses, while immune parameters of her mother were normal. Whole exome sequencing identified a novel mutation in PIK3CD (NM_005026), c.C719T, resulting in p.T240M. Western blot analysis of downstream AKT levels revealed increased basal phosphorylation, in line with gain-of-function mutations of PIK3CD.
Conclusion: The novel missense mutation in PIK3CD occurs in the region encoding the Ras-binding domain (RBD) of p110δ, and likely alters the structural configuration of the domain. To date, pathogenic mutations targeting the RBD of p110δ have not yet been described. Our results expand on the genotypic spectrum of APDS.
Statement of Novelty: We describe a novel mutation in the Ras-binding domain of PIK3CD leading to a presentation of recurrent sinopulmonary and soft tissue infections in the context of APDS.
Formats available
You can view the full content in the following formats:
REFERENCES
Angulo I., Vadas O., Garçon F., Banham-Hall E., Plagnol V., Leahy T.R., Baxendale H., Coulter T., Curtis J., Wu C., Blake-Palmer K., Perisic O., Deborah S., Maes M., Fiddler C., Juss J., Cilliers D., Markelj G., Chandra A., Farmer G., Kielkowska A., Clark J., Kracker S., Debré M., Picard C., Pellier I., Jabado N., Morris J.A., Barcenas-Morales G., Fischer A., Stephens L., Hawkins P., Barrett J.C., Abinun M., Clatworthy M., Durandy A., Doffinger R., Chilvers E.R., Cant A.J., Kumararatne D., Okkenhaug K., Williams R.L., Condliffe A., and Nejentsev S. 2013. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science, 342: 866–871.
Conley M.E., Dobbs A.K., Quintana A.M., Bosompem A., Wang Y.-D., Coustan-Smith E., Smith A.M., Perez E.E., and Murray P.J. 2012. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J. Exp. Med. 209: 463–470.
Coulter T.I., Chandra A., Bacon C.M., Babar J., Curtis J., Screaton N., Goodlad J.R., Farmer G., Steele C.L., Leahy T.R., Doffinger R., Baxendale H., Bernatoniene J., Edgar J.D.M., Longhurst H.J., Ehl S., Speckmann C., Grimbacher B., Sediva A., Milota T., Faust S.N., Williams A.P., Hayman G., Kucuk Z.Y., Hague R., French P., Brooker R., Forsyth P., Herriot R., Cancrini C., Palma P., Ariganello P., Conlon N., Feighery C., Gavin P.J., Jones A., Imai K., Ibrahim M.A.A., Markelj G., Abinun M., Rieux-Laucat F., Latour S., Pellier I., Fischer A., Touzot F., Casanova J.-L., Durandy A., Burns S.O., Savic S., Kumararatne D.S., Moshous D., Kracker S., Vanhaesebroeck B., Okkenhaug K., Picard C., Nejentsev S., Condliffe A.M., and Cant A.J. 2017. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study. J. Allergy Clin. Immunol. 139: 597–606.e4.
Crank M.C., Grossman J.K., Moir S., Pittaluga S., Buckner C.M., Kardava L., Agharahimi A., Meuwissen H., Stoddard J., Niemela J., Kuehn H., and Rosenzweig S.D. 2014. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J. Clin. Immunol. 34: 272–276.
Dulau Florea A.E., Braylan R.C., Schafernak K.T., Williams K.W., Daub J., Goyal R.K., Puck J.M., Koneti Rao V., Pittaluga S., Holland S.M., Uzel G., and Calvo K.R. 2017. Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. J. Allergy Clin. Immunol. 139: 1032–1035.e6.
Elgizouli M., Lowe D.M., Speckmann C., Schubert D., Hülsdünker J., Eskandarian Z., Dudek A., Schmitt-Graeff A., Wanders J., Jørgensen S.F., Fevang B., Salzer U., Nieters A., Burns S., and Grimbacher B. 2016. Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency. Clin. Exp. Immunol. 183: 221–229.
Elkaim E., Neven B., Bruneau J., Mitsui-Sekinaka K., Stanislas A., Heurtier L., Lucas C.L., Matthews H., Deau M.-C., Sharapova S., Curtis J., Reichenbach J., Glastre C., Parry D.A., Arumugakani G., McDermott E., Kilic S.S., Yamashita M., Moshous D., Lamrini H., Otremba B., Gennery A., Coulter T., Quinti I., Stephan J.-L., Lougaris V., Brodszki N., Barlogis V., Asano T., Galicier L., Boutboul D., Nonoyama S., Cant A., Imai K., Picard C., Nejentsev S., Molina T.J., Lenardo M., Savic S., Cavazzana M., Fischer A., Durandy A., and Kracker S. 2016. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: A cohort study. J. Allergy Clin. Immunol. 138: 210–218.e9.
Fruman D.A., Chiu H., Hopkins B.D., Bagrodia S., Cantley L.C., and Abraham R.T. 2017. The PI3K Pathway in Human Disease. Cell, 170: 605–635.
Heurtier L., Lamrini H., Chentout L., Deau M.-C., Bouafia A., Rosain J., Plaza J.-M., Parisot M., Dumont B., Turpin D., Merlin E., Moshous D., Aladjidi N., Neven B., Picard C., Cavazzana M., Fischer A., Durandy A., Stephan J.-L., and Kracker S. 2017. Mutations in the adaptor-binding domain and associated linker region of p110delta cause Activated PI3K-delta Syndrome 1 (APDS1). Haematologica, 102: e278–e281.
Kracker S., Curtis J., Ibrahim M.A.A., Sediva A., Salisbury J., Campr V., Debré M., Edgar J.D.M., Imai K., Picard C., Casanova J.-L., Fischer A., Nejentsev S., and Durandy A. 2014. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. J. Allergy Clin. Immunol. 134: 233–236.e3.
Lucas C.L., Kuehn H.S., Zhao F., Niemela J.E., Deenick E.K., Palendira U., Avery D.T., Moens L., Cannons J.L., Biancalana M., Stoddard J., Ouyang W., Frucht D.M., Koneti Rao V., Atkinson T.P., Agharahimi A., Hussey A.A., Folio L.R., Olivier K.N., Fleisher T.A., Pittaluga S., Holland S.M., Cohen J.I., Oliveira J.B., Tangye S.G., Schwartzberg P.L., Lenardo M.J., and Uzel G. 2014. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 15: 88–97.
Lucas C.L., Chandra A., Nejentsev S., Condliffe A.M., and Okkenhaug K. 2016. PI3Kdelta and primary immunodeficiencies. Nat. Rev. Immunol. 16: 702–714.
Mandola A.B., Dadi H., Reid B., and Roifman C.M. 2020. Novel heterozygous PIK3CD mutation presenting with only laboratory markers of combined immunodeficiency. LymphoSign J. 7: 49–55.
Okkenhaug K. 2013. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31: 675–704.
Okkenhaug K. and Vanhaesebroeck B. 2003. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3: 317–330.
Rae W., Gao Y., Ward D., Mattocks C.J., Eren E., and Williams A.P. 2017. A novel germline gain-of-function variant in PIK3CD. Clin. Immunol. 181: 29–31.
Sharfe N., Nahum A., Newell A., Dadi H., Ngan B., Pereira S.L., Herbrick J.-A., and Roifman C.M. 2014. Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. J. Allergy Clin. Immunol. 133: 807–817.
Sharfe N., Merico D., Karanxha A., Macdonald C., Dadi H., Ngan B., Herbrick J.-A., and Roifman C.M. 2015. The effects of RelB deficiency on lymphocyte development and function. J. Autoimmun. 65: 90–100.
Takeda A.J., Zhang Y., Dornan G.L., Siempelkamp B.D., Jenkins M.L., Matthews H.F., McElwee J.J., Bi W., Seeborg F.O., Su H.C., Burke J.E., and Lucas C.L. 2017. Novel PIK3CD mutations affecting N-terminal residues of p110delta cause activated PI3Kdelta syndrome (APDS) in humans. J. Allergy Clin. Immunol. 140: 1152–1156.e10.
Wang K., Li M., and Hakonarson H. 2010. Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet. 11: 843–854.
Wentink M., Dalm V., Lankester A.C., van Schouwenburg P.A., Schölvinck L., Kalina T., Zachova R., Sediva A., Lambeck A., Pico-Knijnenburg I., van Dongen J.J.M., Pac M., Bernatowska E., van Hagen M., Driessen G., and van der Burg M. 2017. Genetic defects in PI3Kdelta affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clin. Immunol. 176: 77–86.
Zhang K, Husami A, Marsh R, and Jordan MB. 2013. Identification of a phosphoinositide 3-kinase (PI-3K) p110δ (PIK3CD) deficient individual. J. Clin. Immunol. 33: 673–674.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 9 • Number 1 • March 2022
Pages: 11 - 16
History
Received: 14 February 2022
Accepted: 22 February 2022
Accepted manuscript online: 23 February 2022
Copyright
© 2022.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
LauraAbrego Fuentes, JennyGarkaby, OriScott, JessicaWillet Pachul, HarjitDadi, and LindaVong. 2022. Novel mutation in PIK3CD affecting the Ras-binding domain. LymphoSign Journal.
9(1): 11-16. https://doi.org/10.14785/lymphosign-2022-0002
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
